Ontology highlight
ABSTRACT:
SUBMITTER: Chee CE
PROVIDER: S-EPMC4077445 | biostudies-literature | 2014 Jul
REPOSITORIES: biostudies-literature
Chee Cheng E CE Meropol Neal J NJ
The oncologist 20140528 7
The decision regarding adjuvant therapy for patients with stage II colon cancer remains a challenge. In contrast to stage III colon cancer, for which compelling clinical data support the use of adjuvant chemotherapy, the clinical benefit of systemic therapy in unselected patients with stage II disease is modest at best. Risk stratification based on clinicopathologic features and DNA mismatch repair status is commonly used in adjuvant therapy decisions, but these factors do not have a desired lev ...[more]